AlphAIAlphAI — Financial news for AI agents
dailypolitical.comMAY 282 min read$GRBK

New Age Alpha Advisors LLC Acquires New Shares in Green Brick Partners, Inc. $GRBK

New Age Alpha Advisors LLC bought 23,731 shares of Green Brick Partners (NASDAQ:GRBK) in Q4, worth about $1.487M, according to its latest Form 13F; it held ~0.05% at quarter-end. Other funds also adjusted positions. GRBK last reported Q1 EPS of $1.39 vs $1.19 consensus, with revenue down 5.9% y/y.

Original reporting
dailypolitical.com
Published May 28, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 28, 2026, 11:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
New Age Alpha Advisors LLC Acquires New Shares in Green Brick Partners, Inc. $GRBK — source image
Source · dailypolitical.com
Decision brief

The 30-second read

$GRBKBullishLow
01

Why it matters

For traders, the actionable signal is limited: 13F is not a real-time catalyst, and no new guidance or transaction is announced.

02

Market read

Institutional ownership changes and a prior EPS beat may modestly influence sentiment, but the article lacks a fresh fundamental trigger.

03

What to watch

The article highlights revenue down YoY and consensus price target below the current trading range, which could cap upside despite the EPS beat.

Relevance 6/10Novelty 4/10Timing: Post-earnings recap; no new catalyst beyond Q4 13F disclosures.

Background

The piece reports Q4 13F stake changes for Green Brick Partners and reiterates its April 29 quarterly results (EPS beat, revenue down).

Company-level read

Ticker impact

$GRBKBullishMedium confidence
Context

Article cites multiple institutional/hedge-fund 13F changes and notes GRBK’s latest quarter EPS beat versus consensus.

Expected impact

Mild positive drift possible; follow-through depends on next earnings/revisions rather than this 13F recap.

Evidence & confidence

13F flows can signal conviction, but they are backward-looking and the piece doesn’t add incremental fundamentals beyond the already-reported April earnings beat.

Market effects

Sector

Residential homebuilder/land-development sentiment may get a small read-through from institutional positioning, but no sector-wide catalyst is introduced.

Regional

GRBK’s Sun Belt exposure (Dallas/Fort Worth, Houston, Austin, Atlanta) could see marginal sentiment impact if flows reflect confidence in those markets.

Global

Limited; this is company-specific ownership/earnings context rather than a global macro shock.

Counterpoint

What could challenge this read

13F changes may reflect portfolio rebalancing rather than new information; price action may not follow.

Key entities

  • company
    Green Brick Partners, Inc.

    Residential homebuilder and land development firm; subject of the 13F ownership-change recap and recent earnings beat mention.

  • institution
    New Age Alpha Advisors LLC

    Purchased additional GRBK shares per its Q4 13F filing.

Read at source← All news

Related articles

JUL 29
$GRBKMed

GREEN BRICK PARTNERS, INC. REPORTS SECOND QUARTER 2026 RESULTS

Green Brick Partners, Inc. (GRBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 GREEN BRICK PARTNERS, INC. REPORTS SECOND QUARTER 2026 RESULTS PLANO, Texas, July 29, 2026 — Green Brick Partners, Inc. (NYSE: GRBK) (“Green Brick,” “we,” or the “Company”), today announced results for its second quarter ended June 30, 2026. Net income attributable to

SEC EDGAR 8-K6 min
OCT 28
$JHigh

Jacobs unit wins $1B San Francisco wastewater upgrade contract (J:NYSE)

Jacobs (J) secured a $1B contract from the San Francisco Public Utilities Commission for a nutrient reduction project at the Southeast Treatment Plant, aiming to protect San Francisco Bay. The project will enhance wastewater treatment infrastructure. According to Jacobs, this reflects their expertise in environmental solutions. The contract is expected to boost the company's revenue and backlog.

seekingalpha.com1 min
OCT 28
$MLYSHighAI 9/10

Mineralys Therapeutics, Inc. (MLYS) Phase 2 CKD Trial Meets BP Endpoint

Mineralys Therapeutics reported that its Phase 2 Explore-CKD trial met the primary endpoint, with lorundrostat 25 mg reducing systolic blood pressure by 7.5 mmHg vs. placebo at 4 weeks. The treatment also showed reductions in UACR and urine protein, along with a drop in serum aldosterone. The company aims for further trials to confirm sustained benefits and FDA review.

tradingview.com1 min
OCT 28
$MLYSMedAI 9/10

Adding a medicine lowered the top blood pressure reading by 7.5 mmHg vs placebo in a kidney trial

Mineralys Therapeutics (MLYS) reported that its Phase 2 Explore-CKD trial met its primary endpoint, showing a 7.5 mmHg reduction in systolic blood pressure for lorundrostat 25 mg once daily vs. placebo at four weeks. The trial involved 59 participants with uncontrolled hypertension, CKD, and albuminuria. Lorundrostat also reduced urinary protein loss and serum aldosterone levels. The company plans further evaluation of the drug's potential benefits for these conditions.

stocktitan.net2 min